Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Lifecore Biomedical (NASDAQ: LFCR), a contract development and manufacturing organization (CDMO), has announced equity inducement grants for a newly hired employee. The compensation committee approved 15,000 restricted stock units (RSUs) and stock options for 30,000 shares on September 22, 2025.

The RSUs will fully vest after three years, while the stock options will vest one-third after the first year and 1/36th monthly thereafter. The stock options have a seven-year term and an exercise price at Fair Market Value. These grants were made under Lifecore's Equity Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

News Market Reaction – LFCR

-10.70% 1.8x vol

38 alerts

-10.70% News Effect

-11.7% Trough in 3 hr 44 min

-$33M Valuation Impact

$280M Market Cap

1.8x Rel. Volume

On the day this news was published, LFCR declined 10.70%, reflecting a significant negative market reaction. Argus tracked a trough of -11.7% from its starting point during tracking. Our momentum scanner triggered 38 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $33M from the company's valuation, bringing the market cap to $280M at that time. Trading volume was above average at 1.8x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

CHASKA, Minn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on September 22, 2025, the Lifecore compensation committee approved the grant under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of a restricted stock unit (“RSU”) award with respect to 15,000 shares of its common stock and stock options for 30,000 shares of common stock to a newly hired employee of Lifecore. The RSU award and stock options were granted on September 22, 2025, pursuant to the offer letter between Lifecore and the employee, and as a material inducement to the employee joining Lifecore.

The RSU award and stock options were approved by Lifecore’s compensation committee and were granted as inducement equity awards in accordance with Nasdaq Listing Rule 5635(c)(4) under the Inducement Plan.

The RSUs will vest and be settled on the third anniversary of the grant date, subject to continued employment. The stock options have an exercise price equal to Fair Market Value (as defined in the Inducement Plan) on the grant date and will vest as to one-third of the shares on the first anniversary of the grant date and as to 1/36th of the shares on each monthly grant date thereafter, subject to continued employment. The stock options have a seven-year term. The RSU award and stock options are each governed by an award agreement and the Inducement Plan.

About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.

Lifecore Biomedical, Inc. Contact Information:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com

Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com

Ryan D. Lake (CFO)
Lifecore Biomedical
952-368-6244
ryan.lake@lifecore.com

FAQ

What equity grants did Lifecore Biomedical (LFCR) announce on September 23, 2025?

Lifecore announced 15,000 restricted stock units (RSUs) and stock options for 30,000 shares granted to a new employee under their Equity Inducement Plan.

What are the vesting terms for Lifecore's (LFCR) new equity grants?

The RSUs will vest fully after three years, while the stock options vest one-third after the first year and 1/36th monthly thereafter, subject to continued employment.

What is the exercise price for Lifecore's (LFCR) inducement stock options?

The stock options were granted with an exercise price equal to Fair Market Value as defined in the Inducement Plan on the grant date of September 22, 2025.

Why did Lifecore Biomedical (LFCR) issue these equity grants?

The equity grants were issued as material inducement for a newly hired employee joining Lifecore, in accordance with Nasdaq Listing Rule 5635(c)(4).